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transplantationAbstract Aim: Outcomes of children with high-risk (HR) relapsed acute lymphoblastic
leukaemia (ALL) (N Z 393), recruited to ALLR3 and ALL-REZ BFM 2002 trials, were ana-
lysed. Minimal residual disease (MRD) was assessed after induction and at predetermined
time points until haematopoietic stem cell transplantation (SCT).
Methods: Genetic analyses included karyotype, copy-number alterations and mutation analyses.
Ten-year survivals were analysed using Kaplan-Meier and Cox models for multivariable analyses.
Results: Outcomes of patients were comparable in ALLR3 and ALL-REZ BFM 2002. The event-
free survival of B-cell precursor (BCP) and T-cell ALL (T-ALL) was 22.6% and 26.2% (PZ 0.94),
respectively, and the overall survival (OS) was 32.6% and 28.2% (P Z 0.11), respectively. Induc-
tion failures (38%) were associated with deletions of NR3C1 (PZ 0.002) and BTG1 (PZ 0.03) in
BCP-ALL. The disease-free survival (DFS) and OS in patients with good vs poorMRD responses
were 57.4% vs 22.6% (P < 0.0001) and 57.8% vs 32.0% (P Z 0.0004), respectively. For BCP- and
T-ALL, the post-SCT DFS and OS were 42.1% and 56.8% (P Z 0.26) and 51.6% and 55.4%
(P Z 0.67), respectively. The cumulative incidences of post-SCT relapse for BCP- and T-ALL
were 36.9% and 17.8% (P Z 0.012) and of death were 10.7% and 25.5% (P Z 0.013),
respectively. Determinants of outcomes after SCT were acute graft versus host disease, pre-
SCT MRD (103), HR cytogenetics and TP53 alterations in BCP-ALL.
Conclusion: Improvements in outcomes for HR ALL relapses require novel compounds in induc-
tion therapy to improve remission rates and immune targeted therapy after induction to maintain
remission after SCT.
Trial registration: ALLR3: NCT00967057; ALL REZ-BFM 2002: NCT00114348
ª 2021 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY
license (http://creativecommons.org/licenses/by/4.0/).1. Introduction
Duration of first complete remission and immunophe-
notypes predict outcomes in patients with relapsed acute
lymphoblastic leukaemia (ALL) [1e3]. B-cell precursor
(BCP) ALL with bone marrow relapses occurring later
than 6 months after stopping therapy has survival rates
of more than 80% [4,5]. In contrast, patients with high-
risk (HR) relapses defined as BCP-ALL relapses within
18 months of first diagnosis or with isolated medullary
relapses occurring within 6 months of stopping therapy,
and T-cell isolated or combined medullary relapses at any
time, have survival rates between 15% and 30% [3,6,7]
even after allogeneic haematopoietic stem cell trans-
plantation (SCT) [2,3,8e10]. Second complete remission
(CR2) rates in HR patients range between 68% and 88%
[3,9,10]. More recently, HR relapsed patients are
receiving immune-directed therapies. For patients with
HR BCP-ALL, CD19- and CD22-targeted therapies with
the CD19-directed bispecific T-cell engager blinatumo-
mab, the CD22-directed toxin-conjugated monoclonal
antibody inotuzumab ozogamicin [11e16] or chimeric
antigen receptor T-cells (CAR-Ts) [17,18] offer superior
remission rates, although the long-term outcomes of
these novel approaches are awaited.
In this context, we have analysed the long-term out-
comes of HR patients treated in the ALLR3 and ALL-
REZ BFM 2002 clinical trials for relapsed ALL. Both
ALLR3 and ALL-REZ BFM 2002 used a common risk
stratification method and assessed minimal residual dis-
ease (MRD) after induction and before SCT, and all HRpatients were eligible for SCT after 12 weeks of chemo-
therapy. This permitted combining the trial data sets for
patients with HR bone marrow ALL relapses treated in
both trials to evaluate different chemotherapy approaches
for induction remission in HR relapsed ALL and the
relationship of MRD at different time points with sur-
vival, along with additional genetic analyses.
2. Patients and methods
2.1. Study population
This analysis reports on patients with HR (Table 1)
relapsed ALL without a previous SCT, treated in ALLR3
(NCT00967057, N Z 136) or ALL-REZ BFM 2002
(NCT00114348, N Z 257) trials. Early isolated extra-
medullary relapses were excluded. Patients at the age be-
tween 1 and 18 years at relapse diagnosis were included in
theanalyses.Trialswere approvedby relevant institutional
ethical committees, and patients were recruited after
written consent between 28th December 2001 and 18th
June 2011 (ALL-REZ BFM 2002) and between 31st
January 2003 and 31stOctober 2013 (ALLR3).
2.2. Therapy
Chemotherapy for ALL-REZ BFM 2002 [8] and
ALLR3 [19] has been previously reported and is briefly
described in the supplemental section (Supplemental
Table S1). ALLR3 randomised patients to idarubicin
or mitoxantrone in induction, and early closure of the
Table 1


















Very early HR/IR* HR HR HR/IR* HR HR
Early IR IR HR IR HR HR
Late SR IR IR SR HR HR
HR, high risk; IR, intermediate risk; SR, standard risk; ALL, acute lymphoblastic leukaemia.
HR/IR* were HR in ALLR3 and IR in ALL-REZ BFM 2002 and excluded from this study. Patients classified as HR categories in bold are included
in this analysis.
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the evaluation of clofarabine, cyclophosphamide and
etoposide (CCE) in induction.
2.3. Assessment of response
CR2 was defined as <5% blasts in the marrow and no
blasts in the cerebrospinal fluid (CSF) at the end of
induction (EOI)dotherwise defined as induction fail-
ure. MRD was measured after induction and in some
patients after each block of therapy before SCT, with
the validated and standardised real-time quantitative
polymerase chain reaction assays for clonal gene rear-
rangements in immunoglobulin/T-cell receptor loci
[8,19]. Two postinduction MRD response groups were
defined. The good response (GR) group was that with
an MRD of <104 at the EOI or between 104 and
<103 at the EOI, with a subsequent MRD value of
<104 after induction. All others were defined as poor
response (PR).
2.4. Cytogenetics and molecular genetics
Fusion genes (ETV6-RUNX1, TCF3-PBX1, KMT2A-
AFF1 and KMT2A-MLLT1) or aneuploidies (high
hyperdiploid, low hypodiploid, near-haploidy) were
detected as described previously [20e23]. Patients were
grouped into standard risk (SR), HR and B-other
groups by integrating cytogenetic and genetic data as
reported for relapsed ALL. Copy number status of
IKZF1, CDKN2A/B, PAX5, EBF1, ETV6, BTG1, RB1,
NR3C1 and PAR1 was determined using the SALSA
multiplex ligation-dependent probe amplification kit
P335; TP53 deletions by the P007 or P056 kit (MRC
Holland, The Netherlands). Key exons of TP53, NRAS,
KRAS, PTPN11, FLT3 and CBL genes were assessed
for mutations by denaturing high-performance liquid
chromatography and/or Sanger sequencing [21,22].
2.5. Statistical analysis
Survival analysis considered five main end-points.
Event-free survival (EFS) was calculated as the time
from first relapse, using the date of relapse, until the firstevent (induction death, induction failure, second
relapse, death in CR2 and second malignancy) or last
follow-up. Disease-free survival (DFS) included only
patients who achieved CR2 and was calculated as the
time from first relapse until the first event (second
relapse, death, second malignancy) or last follow-up.
For outcomes after SCT, the date of SCT was used as
the starting point for DFS. Overall survival (OS) was
defined as time from first relapse to death censoring at
the last contact. Cumulative incidence of subsequent
relapses (CIR) or cumulative incidence of death (CID)
was calculated as the time from first relapse until second
relapse or death in CR2, taking other DFS events into
account as competing events. EFS, DFS and OS prob-
abilities and cumulative incidence functions for
competing events are given at 10 years in the following
Results and Discussion sections. Further details are in
Supplemental section.
3. Results
3.1. Comparison of patients treated uisng the different
regimens
Twenty-five, 60 and 51 HR ALLR3 patients received
idarubicin, mitoxantrone, CCE arms; 257 patients ALL-
REZ BFM 2002 respectively (Supplemental Results).
CR2 rates and EFS were comparable within the different
treatment protocols for both BCP-ALL and T-cell ALL
(T-ALL) (Fig. 1, Table 2). As the EFS of the different
therapeutic groups was comparable, data from all 393
patients were combined to further investigate the de-
terminants of outcomes in HR relapsed ALL.
3.2. Overall outcomes of the combined cohort
Two hundred seventy-eight (71%) patients had BCP-
ALL, and 115 (29%) had T-ALL. Progression through
treatment for the patients with BCP- andT-ALL is shown
in Fig. 1 and for the whole cohort is shown in
Supplementary Fig. S1. The proportion of patients
attaining CR2 and reaching SCT was comparable be-
tween the two groups. The EFS and OS were 22.6% (95%
confidence interval [CI]: 17e29) and 26.2% (18e35) as
Fig. 1. CONSORT diagramdschematic of outcomes of patients with high-risk relapsed ALL with (A) B-cell precursor ALL and (B) T-cell
ALL. ALL, acute lymphoblastic leukaemia; BCP, B-cell precursor, T, T-cell; CR2, second complete remission; TRM, therapy-related
mortality; FU, follow-up; SCT, stem cell transplantation; SM, secondary malignancy; CCR2, second continuous complete remission.
C. Eckert et al. / European Journal of Cancer 151 (2021) 175e189178well as 32.6% (27e39) and 28.2% (20e37), for BCP- and
T-ALL, respectively (Fig. 2). Although outcomes of pa-
tients with BCP-ALL and T-ALL relapse were compa-
rable, T-ALL relapses at any time point are classified as
HR. In this cohort, 25% of T-ALLwere late relapses, and
these patients were more likely to achieve CR2 (Table 3).
3.3. Determinants of induction failure
Overall, for both BCP- and T-ALL, 4% of patients died
in induction and 34% of patients failed induction
(Fig. 1). Induction failures were more frequent in those
relapsing within 18 months from first diagnosis in both
BCP- and T-ALL (P Z 0.020and P Z 0.017, respec-
tively), in older children with BCP-ALL (P Z 0.012)
and in BCP-ALL with isolated medullary relapse
(PZ 0.040). None of these factors appeared to influenceTable 2




N 51 25 60
EFS, % (95% CI)
All patients
Total 22.0 (12e35) 16.0 (5e33) 28.0 (17e40)
BCP-ALL 17.7 (6e34) 15.8 (4e35) 27.8 (15e42)
T-ALL 27.8 (11e48) 16.7 (1e52) 28.6 (12e48)
Excluding induction failures
Total 32.1 (17e48) 20.0 (6e39) 39.9 (25e54)
OS, % (95% CI)
All patients
Total 21.2 (11e34) 16.0 (5e33) 31.0 (20e43)
BCP-ALL 16.8 (6e33) 15.8 (4e35) 30.1 (17e45)
T-ALL 27.2 (10e47) 16.7 (1e52) 33.3 (15e53)
Excluding induction failures
Total 31.4 (16e48) 20.0 (6e39) 39.8 (25e54)
ALL, acute lymphoblastic leukaemia; CCE, clofarabine, cyclophosphami
confidence interval; T, T-cell.
a Compares outcomes between mitoxantrone (ALLR3) and REZ 2002; pEFS in those who achieved CR2 (Table 3). Induction
failures were more frequent in patients with cytogenetic
HR BCP-ALL (48%) than in cytogenetic SR (24%) and
B-other patients (31%, P Z 0.032), especially those with
hypodiploidy (64%, P Z 0.017) and associated with
deletions of BTG1 and NR3C1 (P Z 0.031, P < 0.001;
Table 4). Eighteen (15%) of 123 patients with induction
failures subsequently achieved remission, 9 with
continuing protocol treatment and 9 with alternative
treatment strategies.
3.4. Postinduction MRD response and correlation to
outcomes
One hundred seventy-eight patients with BCP-ALL and
74 patients with T-ALL achieved CR2 (Fig. 1). A second
relapse before SCT occurred in 18 of 140 patients (13%)3 and ALL-REZ BFM 2002 protocols.




21.3 (14e30) 25.1 (20e31) 0.44 0.60
19.3 (11e30) 24.2 (18e32) 0.51 0.57
25.2 (14e39) 26.9 (17e38) 0.93 0.83
29.8 (20e41) 47.7 (33e50) 0.0067 0.67
22.3 (15e31) 35.9 (30e42) 0.0001 0.30
20.3 (12e31) 38.0 (31e45) 0.0002 0.28
27.3 (15e41) 30.0 (19e41) 0.51 0.42
29.4 (19e40) 49.2 (41e57) 0.0001 0.22
de and etoposide; EFS, event-free survival; OS, overall survival; CI,
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Fig. 2. Comparable outcomes of patients with high-risk relapse of BCP-ALL and T-ALL. Kaplan-Meier analyses of event-free (A) and
overall (B) survival in BCP- and T-ALL high-risk relapsed ALL. ALL, acute lymphoblastic leukaemia; BCP, B-cell precursor; T, T-cell;
CI, confidence interval.
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(P Z 0.0157, Fig. 1). The EOI MRD thresholds for the
ALL-REZ BFM 2002 [8] and ALLR3 [19] trials were
103 and 104, respectively. DFS and OS were signifi-
cantly better in those with an EOI MRD of <103 inTable 3
Determinants of induction failure in patients with high-risk relapsed ALL.
Risk factors Determinants All patients excluding ind
Na CR2,
BCP-ALL 265 178 (6
Sex Male 156 104 (6
Female 109 74 (68
Age at relapse Median, 95% CI (years) 6.7 (4.5e13.1) 6.5 (6.
<10 years 167 124 (7
10e14 years 49 25 (14
15 years 49 29 (16
Time to relapse Very early 113 67 (59
Early 151 110 (7
Site of relapse Bone marrow isolated 251 165 (6
Bone marrow combined 14 13 (93
T-ALL 110 74 (76
Sex Male 81 56 (69
Female 29 18 (62
Age at relapse Median, 95% CI (years) 9.9 (6.8e14.8) 9.5 (9e
<10 years 55 40 (54
10e14 years 30 18 (24
15 years 25 16 (22
Time to relapse Very early 55 32 (58
Early 27 18 (67
Late 27 24 (89
Site of relapse Bone marrow isolated 76 50 (66
Bone marrow combined 34 24 (71
ALL, acute lymphoblastic leukaemia; CR2, second complete remission; BC
T, T-cell.
P values in bold indicate those <0.05.
a Induction deaths are excluded.
b p values are calculated using the chi-square test.
c p values are calculated using the log-rank test.both trials, but in ALLR3 only, these were better in
those with an EOI MRD of <104 (Table 5). Poten-
tially, this discordance in the relationship of EOI MRD
with survival relates to the use of anthracyclines in in-
duction for ALLR3. ALL-REZ BFM 2002 usesuction deaths Patients reached CR2
N (%) Induction
failure, N (%)
Pb DFS, % 95% CI Pc
7) 87 (33)
7) 52 (33) 0.84 38.1 29e48 0.96
) 35 (32) 32.5 19e47
0e7.6) 10 (6e12) 0.012
0) 43 (49) 0.004 35.1 26e45 0.74
) 24 (28) 35.1 13e59
) 20 (23) 39.4 22e57
) 46 (41) 0.020 41.4 29e54 0.84
3) 41 (27) 31.7 21e49
6) 86 (34) 0.040 34.2 26e43 0.44
) 1 (7) 53.9 25e76
) 36 (24)
) 25 (31) 0.49 42.9 29e55 0.78
) 11 (38) 36.4 15e58
11) 11.5 (7e14) 0.65
) 15 (42) 0.45 40.7 25e56 0.27
) 12 (33) 55.0 29e75
) 9 (25) 25.0 8e47
) 23 (42) 0.017 36.5 20e53 0.58
) 9 (33) 37.0 16e59
) 3 (11) 48.4 37e67
) 26 (34) 0.62 45.2 31e58 0.37
) 10 (29) 31.1 14e50
P, B-cell precursor; DFS, disease-free survival; CI, confidence interval;
Table 4
Genetic determinants of induction failure: BCP-ALL.





ETV6-RUNX1 fusion Yes 12 5 10 (83) 2 (17) 0.35
No 229 95 151 (66) 78 (34)
NA 24 17 7
High-hyperdiploid Yes 26 11 19 (73) 7 (27) 0.47
No 215 89 142 (66) 73 (34)
NA 24 17 7
iAMP21 Yes 3 1 3 (100) 0 0.55
No 238 99 158 (66) 80 (34)
NA 24 17 7
KTM2A fusions Yes 21 9 13 (62) 8 (38) 0.62
No 220 91 148 (67) 72 (33)
NA 24 17 7
TCF3-HLF, TCF3-PBX1 Yes 12 5 5 (42) 7 (58) 0.058
No 229 95 156 (68) 73 (32)
NA 24 17 7
Hypodiploid (<40 Chr) Yes 14 6 5 (36) 9 (64) 0.017
No 227 94 156 (69) 71 (31)
NA 24 17 7
Cytogenetic risk groups
B-other 153 63 106 (69) 47 (31) 0.032
Cyto-SR 38 16 29 (76) 9 (24)
Cyto-HR 50 21 26 (52) 24 (48)
NA 24 17 7
Genetic alterations
IKZF1del Yes 54 30 30 (56) 24 (44) 0.16
No 129 70 86 (54) 43 (46)
NA 82 62 20
CDKN2A/Bdel Yes 85 46 56 (66) 29 (34) 0.51
No 98 54 60 (61) 38 (29)
NA 82 62 20
ETV6del Yes 25 14 12 (48) 13 (52) 0.078
No 157 86 104 (66) 53 (34)
NA 83 62 21
PAX5del Yes 44 24 27 (61) 17 (39) 0.72
No 138 76 89 (65) 49 (36)
NA 83 62 21
BTG1del Yes 12 7 4 (33) 8 (67) 0.031
No 170 93 112 (66) 58 (34)
NA 83 62 21
RB1del Yes 4 2 2 (50) 2 (50) 0.62
No 178 98 114 (64) 64 (36)
NA 83 62 21
EBF1del Yes 6 3 4 (67) 2 (23) 1.00
No 176 97 112 (64) 64 (36)
NA 83 62 21
NR3C1del Yes 7 14 2 (29) 5 (71) 0.002
No 44 86 39 (89) 5 (11)
NA 214 137 77
PAR1del Yes 16 9 10 (63) 6 (27) 0.89
No 165 91 106 (64) 59 (36)
NA 84 62 22
TP53 alteration Yes 34 20 19 (56) 15 (44) 0.32
No 171 80 111 (65) 60 (35)
NA 60 48 12
NRASmut Yes 33 18 21 (64) 12 (36) 0.98
No 152 82 97 (64) 55 (36)
NA 80 60 20
KRASmut Yes 30 16 16 (53) 14 (47) 0.22
No 155 84 102 (66) 53 (34)
NA 80 60 20
IKZF1/NR3C1/BTG1 Yes 73 55 39 (53) 34 (47) <0.001
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Table 4 (continued )
BCP-ALL genetic groups N %a CR2, N (%) Induction
failure, N (%)
Pb
No 60 45 50 (83) 10 (17)
NA 132 78 43
IKZF1plusc Yes 67 37 23 (54) 20 (47) 0.123
No 116 63 93 (66) 47 (34)
NA 82 62 20
ALL, acute lymphoblastic leukaemia; BCP, B-cell precursor; CR2, second complete remission; cyto-SR, cytogenetic standard risk (ETV6-RUNX1,
high-hyperdiploid); cyto-HR, cytogenetic high risk (<40 Chr., KTM2A, TCF3-HLF, TCF3-PBX1, iAMP21); NA, not analysed (data were
excluded from the analyses); del, deletion; mut, mutation; NA, not available.
P values in bold indicate those <0.05.
a Percentage of numbers available for analyses.
b p values were estimated using the chi-square test or Fisher’s exact test (n < 5).
c ERG deletions not assessed.
Table 5
Disease-free survival and overall survival based on end of induction MRD levels.
MRD level 10e4 10e3
<  P <  P
ALLR3 N 23 43 30 21
DFS, % 55.9 (30e76) 14.9 (5e29) 0.0011 45.8 (26e64) 32.2 (19e46) 0.0018
OS, % 55.7 (30e75) 14.4 (5e29) 0.001 44.5 (24e63) 7.1 (1e26) 0.0019
ALL-REZ BFM 2002 N 28 90 51 66
DFS, % 57.1 (37e73) 36.0 (24e48) 0.1 58.6 (44e71) 27.0 (13e43) 0.0037
OS, % 56.0 (35e72) 46.7 (36e57) 0.26 59.9 (45e72) 41.1 (29e53) 0.018
MRD, minimal residual disease; DFS, disease-free survival; OS, overall survival.
Discrepancies of patient numbers between the 104 and 103 cut-off groups are due to sensitivity of MRD markers (only 103 or 5  104, but not
104) or the non-available quantitative MRD values to assign the MRD results to one of the positive MRD groups, either 103 or <103e104.
P values in bold indicate those <0.05.
Table 6
Outcomes of patients with high-risk relapsed ALL based on MRD response.
MRD Na DFS (%) 95% CI Pb CIR (%) 95% CI Pc OS (%) 95% CI Pb
BCP-ALL
EOI <104 38 58.9 14e73 0.012 23.9 12e39 0.012 58.2 40e73 0.053
EOI 104 100 28.9 18e41 48.0 38e58 39.5 30e49
EOI <103 60 58.4 44e70 0.0005 27.1 16e39 0.0026 59.9 46e71 0.0066
EOI 103 67 20.8 8e37 52.2 40e63 34.5 23e47
GR 48 60.0 44e73 0.0005 23.6 13e37 0.0018 62.0 46e75 0.004
PR 75 23.4 11e38 50.7 39e61 35.5 24e47
T-ALL
EOI <104 13 52.8 23e76 0.087 31.9 9e58 0.31 49.2 19e74 0.075
EOI 104 33 29.6 15e46 45.5 28e62 27.6 13e44
EOI <103 21 42.3 21e62 0.12 38.6 18e59 0.45 39.6 18e60 0.074
EOI 103 20 25.0 9e45 45.0 22e65 25.0 9e45
GR 16 49.2 24e71 0.016 25.8 7e50 0.036 46.3 20e69 0.019
PR 24 20.8 8e39 54.1 32e72 20.8 8e35
BCP- and T-ALL
EOI <104 51 57.4 42e69 0.0025 25.8 15e39 0.0070 55.4 40e69 0.011
EOI 104 133 28.9 19e39 47.5 39e56 36.7 28e45
EOI <103 81 54.3 43e64 0.00024 30.0 20e40 0.0029 54.3 42e65 0.0019
EOI 103 87 21.7 11e35 50.6 40e61 32.7 23e43
GRd 64 57.4 44e69 <0.0001 24.1 14e35 0.0002 57.8 44e70 0.0004
PRd 99 22.6 13e35 51.5 41e61 32.0 23e42
ALL, acute lymphoblastic leukaemia; CI, confidence interval; DFS, disease-free survival; CIR, cumulative incidence of relapses; OS, overall
survival; MRD, minimal residual disease; BCP, B-cell precursor; EOI, end of induction; GR, good response; PR poor response; T, T-cell.
P values in bold indicate those <0.05.
a Total numbers between the three MRD categories (EOI </104, EOI </103, GR/PR) vary because of the sensitivity of MRD markers or
missing MRD time points after induction.
b p values calculated using the log-rank test.
c p values calculated using the Gray test.
d MRD good response was defined as either <104 at the end of induction or <103 at the end of induction and subsequent MRD values during
consolidation/before SCT <104. The MRD poor response group included all other responses, 104 at the end of induction and one or more
subsequent MRD values during consolidation/before SCT 104.
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Fig. 3. Different disease-free survival, overall survival and cumulative incidence of subsequent relapses in patients with MRD good vs
MRD poor response after induction treatment. Kaplan-Meier analyses of disease-free (A) and overall (B) survival and cumulative
incidence of subsequent relapses and death (C) in patients who were in CR and MRD until SCT was measured. CR, complete remission;
CI, confidence interval; CIR, cumulative incidence of relapses; CID, cumulative incidence of death; MRD, minimal residual disease; BCP,
B-cell precursor; ALL, acute lymphoblastic leukaemia; GR, good response; PR poor response.
C. Eckert et al. / European Journal of Cancer 151 (2021) 175e189182anthracycline after induction. As EFS in both trials was
comparable, we analysed EOI and post-EOI MRD
values as MRD-GR and MRD-PR. Grouped as MRD-
GR and MRD-PR, DFS, CIR and OS were significantly
better for patients with MRD-GR for both BCP- and T-
ALL (Table 6 and Fig. 3). In BCP- or T-ALL, clinicalTable 7
MRD before SCT and disease-free/overall survival in all patients.
MRD before
SCT
N DFS in %
(95% CI)
P OS in %
(95% CI)
P
<104 76 47.0 (35e59) 0.046 49.2 (37e61) 0.02
103e104 11 45.5 (17e71) 45.5 (17e71)
103 11 18.2 (3e44) 18.3 (3e44)
CI, confidence interval; SCT, stem cell transplantation; MRD, mini-
mal residual disease; DFS, disease-free survival; OS, overall survival.
P values in bold indicate those <0.05.risk parameters (Supplemental Table S3) or cytogenetic/
genetic parameters (Supplemental Table S4) in BCP-
ALL did not distinguish between MRD-GR and
MRD-PR, although numbers in each group were small.
The EOI MRD results were available in 18 of the 33
patients relapsing before SCT. Sixteen (89%) had an
EOI MRD of 103, 6 had an EOI MRD of 102 and
one had an EOI MRD of <104. MRD was not avail-
able for 89 (35%) of 252 patients in CR2 (Table 6) and is
detailed in Supplemental Table S5.
3.5. Determinants of outcomes after SCT
Of the 207 patients who reached the SCT time point, 183
(88%) received anSCT, 18did not receive anSCTandSCT
status was unknown for 6 patients (Fig. 1). The DFS and
OS of patients who received an SCT and who did not
Table 8
Multivariable Cox regression analysis for disease-free survival and overall survival after SCT.
Parameter N Hazard ratio 95% CI P
Disease-free survival
Univariate
MRD after induction GR 56 1.00
PR 73 1.80 1.09e2.97 0.022
MRD before SCT <103 88 1.00
103 14 2.56 1.12e5.76 0.026
Cytogenetic risk group B-other 81 1.00
Cyto-SR 22 0.86 0.44e1.66 0.65
Cyto-HR 18 1.77 0.93e3.36 0.082
TP53 alteration No 85 1.00
Yes 12 2.63 1.31e5.27 0.006
aGVHD Yes 56 1.00
No 20 2.17 1.13e4.14 0.020
Multivariable
MRD before SCT <103 63 1.00
103 8 2.79 1.19e6.53 0.018
Cytogenetic risk group B-other 45 1.00
Cyto-SR 14 1.15 0.51e2.57 0.72
Cyto-HR 12 2.58 1.15e5.77 0.021
Overall survival
Univariate
MRD after induction GR 56 1.00
PR 73 1.55 0.92e2.60 0.098
MRD before SCT <103 88 1.00
103 14 2.71 1.18e6.19 0.018
Cytogenetic risk group B-other 81 1.00
Cyto-SR 22 0.98 0.49e1.96 0.95
Cyto-HR 18 2.18 1.13e4.19 0.020
TP53 alteration No 85 1.00
Yes 12 2.8 1.38e5.66 0.004
aGVHD Yes 56 1.00
No 20 2.48 1.23e5.00 0.012
Multivariable
MRD before SCT <103 63 1.00
103 8 3.11 1.31e7.37 0.010
Cytogenetic risk group B-other 45 1.00
Cyto-SR 14 1.14 0.49e2.68 0.72
Cyto-HR 12 3.03 1.34e6.83 0.008
CI, confidence interval; MRD, minimal residual disease; GR, good response; PR, poor response; SCT, stem cell transplantation; cyto-SR, cyto-
genetic standard risk (ETV6-RUNX1, high-hyperdiploid); cyto-HR, cytogenetic high-risk (<40 Chr., KTM2A, TCF3-HLF, TCF3-PBX1,
iAMP21); aGVHD, acute graft-versus-host disease.
Cox regression analysis includes all significant univariate variables: MRD after induction and before SCT, cytogenetic risk group, TP53
alterations and aGVHD. Overlap of cytogenetic HR and aGVHD is small here (n Z 1), and a model with cytogenetic stepwise forward testing,
comparison of models using a log-likelihood ratio test risk group and aGVHD, is not possible.
P values in bold indicate those <0.05.
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(0.5e26) as well as 52.7% (45e60) and 13.3% (2e34),
respectively. CR2 after SCTwasmaintained in 61 (47%) of
131 patients with a BCP-ALL relapse and 30 (58%) of 52
patients with a T-ALL relapse, with a DFS and OS of
patients after SCTof 42.1% (32e52) and 56.8% (42e69) as
well as 51.6% (42e60) and 55.4% (40e68), respectively.
For patients with BCP-ALL only, univariable analyses
of variables affecting post-SCT survival identified acute
graft-versus-host disease (GVHD), DFS 64% (60e75) with
vs 25% (9e45) without acute GVHD (aGVHD) and OS
51%(33e67) and30% (12e50), respectively, andapre-SCT
MRD <103 (DFS: 56% (43e67)) vsMRD 103 (DFS:13% (7e42)) and OS: 47% (33e59) vs 12.5% (7e42),
respectively. Survivalwas concordant between the pre-SCT
MRD groups of <103e104 and <104 (DFS: 46%
(17e71), 47% (35e59) andOS: 46% (17e71), 49% (37e61))
(Table 7). In patientswithout aGVHD, 14of 15 eventswere
a second relapse.Amongpatientswith aBCP-ALL relapse,
DFS after SCT was lower in patients with hypodiploidy
(P Z 0.0002), a TCF3 rearrangement (P < 0.0001) or a
TP53del/mut (P Z 0.002), although numbers in each group
were small (Supplemental Table S6). Multivariable ana-
lyses forDFSandOSconfirmed apre-SCTMRDof103
and no aGVHD as independent predictors of poor out-
comes after SCT in BCP-ALL (Table 8). For patients with
Table 9
Determinants of outcomes after SCT.
Risk factors BCP-ALL T-ALL
N DFS 95% CI P OS 95% CI P N PFS 95% CI P OS 95% CI P
Sex Male 78 50.6 39e61 0.78 50.1 39e62 0.72 38 60.1 43e74 0.37 58.7 41e73 0.33
Female 53 54.2 40e67 36.6 19e54 14 47.1 20e71 46.8 20e70
Age at relapse (years) <10 89 50.0 74e99 0.40 45.1 33e56 0.71 27 61.4 40e77 0.38 55.6 35e72 0.71
10e15 24 50.0 29e68 32.1 8e61 15 60.0 32e80 64.3 34e83
15 18 65.5 4e8 58.2 32e78 10 40.0 12e67 44.0 14e72
Time to relapse Very early 47 57.2 42e70 0.45 56.4 39e70 0.16 20 54.2 30e73 0.99 51.7 27e72 0.89
Early 84 49.4 38e60 37.7 24e52 11 57.1 25e80 62.3 28e84
Late e e 21 55.5 32e74 55.3 32e74
Site of relapse Isolated 121 50.7 41e59 0.32 42.1 31e53 0.14 37 57.2 40e71 0.60 57.2 39e72 0.60
Combined 10 70.0 33e89 80.0 41e95 15 50.9 24e73 50.3 23e72
Donor type MMD 26 38.5 20e56 0.29 38.5 20e56 0.28 13 60.6 29e81 0.95 60.1 29e81 0.95
MRD 19 46.8 24e67 33.7 8e63 12 54.0 22e78 48.6 15e76
MUD 79 57.8 46e68 51.1 38e63 23 56.5 34e74 54.8 32e73
SC source BM 66 57.3 44e68 0.13 42.6 26e58 0.073 24 61.1 38e78 0.63a 59.3 36e77 0.64a
PBSC 37 39.9 24e55 37.5 22e53 20 54.6 31e73 53 29e72
CB 12 58.3 27e80 66.7 34e86 3 0.0 0.0
TBI Yes 113 52.6 43e61 0.83 43.8 32e55 0.45 45 54.4 39e68 0.76 52.6 36e67 0.80
No 15 52.5 25e74 59.3 31e79 5 60.0 13e88 60.0 13e88
aGVHD Yes 56 64.2 50e75 0.0042 51.4 33e67 0.027 23 56.5 34e74 0.32 55.9 36e73 0.35
No 20 25.0 9e45 30.0 12e50 10 40.0 12e67 40.0 12e67
cGVHD Yes 10 90.0 47e99 0.11 45.0 1e80 0.49 11 45.5 17e71 0.94 45.5 17e71 0.90
No 48 62.4 47e74 59.9 44e73 17 52.9 28e73 52.9 28e73
MRD pre-SCT
<103 68 55.6 43e67 0.035 46.5 33e59 0.036 20 43.8 22e64 0.16 41.9 20e63 0.96
103 8 12.5 7e42 12.5 1e42 6 16.7 8e52 16.7 8e52
<104 58 58.4 40e74 0.085 47.4 33e61 0.12 18 42.9 20e64 0.30 40.5 17e63 0.30
>104 17 29.4 11e51 29.4 11e51 8 25.0 4e56 25.0 4e56
MRD post-induction
<103 49 61.3 46e74 0.0703 61.3 46e74 0.07 12 57.1 25e80 0.22 53.3 12e78 0.24
103 50 28.1 11e48 28.1 11e48 23 38.7 19e58 36.6 17e56
<104 33 58.8 40e74 0.29 58.8 40e74 0.29 19 46.8 24e67 0.47 43.8 20e65 0.31
104 76 36.1 22e51 36.1 22e51 14 35.7 13e59 35.7 13e59
GRb 40 64.1 47e77 0.073 59.7 42e74 0.099 16 49.2 24e71 0.30 46.3 20e69 0.26
PRb 58 46.6 33e59 30.6 15e48 15 33.3 12e56 33.3 12e56
ALL, acute lymphoblastic leukaemia; CI, confidence interval; SCT, stem cell transplantation; T, T-cell; BCP, B-cell precursor; MMD, mismatched donor; MRD, matched related donor; MUD,
matched unrelated donor; BM, bone marrow; PBSC, peripheral blood stem cell; CB, cord blood; TBI, total body irradiation; aGVHD, acute graft-versus-host disease; cGHVD, chronic graft-versus-
host disease; MRD pre-SCT/MRD post-induction, minimal residual disease before SCT/minimal residual disease after induction treatment; SC, stem cell.
P values in bold indicate those <0.05.
a The p value excludes CB; p values calculated using the log-rank test.
b MRD good response was defined as either <104 at the end of induction or <103 at the end of induction and subsequent MRD values during
consolidation/before SCT <104. The MRD poor response group included all other responses, 104 at the end of induction and one or more














































BCP-ALL, n = 131, CIR 36.9% (29-45)
T-ALL, n = 52, CID 25.5% (14-38)
BCP-ALL, n = 131, CID 10.7% (6-17)
T-ALL, n = 52, CIR 17.8% (9-30)
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Fig. 4. Higher cumulative incidence of subsequent relapses in
patients with high-risk BCP-ALL, but of death in patients with T-
ALL after SCT. Cumulative incidence of subsequent relapses and
death in patients with BCP- and T-ALL who underwent SCT.
CIR, cumulative incidence of relapses; CID, cumulative incidence
of death; BCP, B-cell precursor; T, T-cell; ALL, acute lympho-
blastic leukaemia; SCT, stem cell transplantation.
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after SCT (Table 9).
Of 183 patients, who received an SCT, transplant-
related mortality occurred in 27 (15%) and relapse after
SCT occurred in 57 (31%) patients. The CIR and CID
after SCT were 31.6 (25e38) and 14.9 (10e21), respec-
tively. The CIR and CID for BCP- vs T-ALL wereFig. 5. Heterogeneous patterns of event occurrence before and after SC
end of induction treatment. Disease-free survival of patients with B-cell
different phases of treatment are highlighted in different grey scales and
4 Z SCT). ALL, acute lymphoblastic leukaemia; SCT, stem cell trans36.9% (29e45) and 17.8% (9e30) as well as 10.7%
(6e17) and 25.5% (14e38, Fig. 4), respectively, sug-
gesting an increase in post-SCT relapses in BCP-ALL
and transplant-related mortality in T-ALL.
4. Discussion
The outcomes of HR relapsed ALL treated in the two
trials were similar, allowing observations to be made on
a combined analysis of prospectively treated and uni-
formly defined HR relapsed ALL. Nevertheless, the data
need to be interpreted cautiously as a number of patients
were withdrawn because of toxicity with idarubicin and
CCE, the study population was heterogeneous,
numbers in subgroup analyses were small and the me-
dian follow-up time is variable in the different groups,
although most events occurred within 36 months. The
trials also accrued patients between 2001 and 2013.
Although the data are mature, during the current era,
there have been improvements in transplant outcomes
and the availability of immunotherapies. The results
show comparable outcomes for both BCP- and T-ALL
HR relapse with a benefit for SCT. The results of this
paper confirm previous observations of poor outcomes
in older patients [24], relapses within 18 months of
diagnosis, with isolated medullary relapse [2] and with
HR cytogenetics [22]. Neither the donor nor the stem
cell source influenced outcomes [25].T in patients with high-risk relapses in complete remission at the
precursor ALL and T-cell ALL in second complete remission. The
numbered (1 Z induction; 2Z consolidation; 3 Z intensification;
plantation.
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in EOI MRD responses, the survival rates were similar.
Those with an EOI MRD of <104 or those with an
EOI MRD of 104e<103 with sequential decrease in
MRD had the best outcomes, possibly reflecting sensi-
tivity of residual cells to concurrent therapy. Thus, in
HR relapses, serial assessment of MRD may better
guide subsequent therapeutic interventions. Pre-SCT
MRD levels of 103 [26,27] and 104 [5,28] have
been reported to be associated with poor outcomes after
SCT. In this cohort, a pre-SCT MRD of <104 and
104e<103 was associated with comparable out-
comes, and only those with an MRD of 103 showed a
significantly poorer outcome. Methodologically newer
MRD assays (next-generation sequencing) may further
increase the sensitivity of detecting lower levels of MRD
[29]. Nevertheless, patients with low or absence of MRD
before SCT relapsed after SCT in our cohort. MRD
kinetics vary with different ALL subtypes, with MRD
being less predictive of relapses in HR cytogenetic sub-
types and T-ALL [30]. We speculate that in T-ALL,
there may also be extramedullary reservoirs of disease
[31] not readily assessed using marrow-based MRD as-
says only.
aGVHD appeared to be associated with a graft-
versus-leukaemia effect in BCP-ALL but not in T-ALL
in this cohort. Patients with T-ALL also had a higher
post-SCT therapyerelated mortality. A 3-year therapy-
related mortality of 30% with an OS of 48% has been
reported for 229 patients with T-ALL who underwent
transplantation in CR2, with no impact of acute or
chronic GVHD on the outcome [32]. Our study does not
have the required data to provide a satisfactory expla-
nation for the apparent benefit of aGVHD in BCP-ALL
or the increased transplant-related toxicity in T-ALL,
and this requires further prospective evaluation.
Achieving a second remission remains a major
problem. Addition of the proteasomal inhibitor borte-
zomib to induction therapy in relapsed ALL has been
reported to achieve CR2 rates of 63e72%, benefitting
both BCP- and T-ALL, and was well tolerated [33,34].
Of those reaching SCT, other than high MRD, recur-
rence was seen more frequently in those with a TCF3
rearrangement, TP53del/mut or hypodiploidy [35]. Pre-
clinical data suggest that TCF3-rearranged and hypo-
diploid ALL may be susceptible to the BCL-2 inhibitor
venetoclax [36,37] and that TP53-rearranged ALL may
be susceptible to a combination of APR-246 and
doxorubicin [38].
Given the genetic heterogeneity of ALL, targeting sur-
face epitopes with immunotherapy offers a more uniform
strategy [39]. Recent studies [12,13,16] reported impressive
MRD responses and outcomes with minimal toxicities
after CD19-directed therapy using blinatumomab or
CAR-T therapy. In this study, for patients with BCP-ALL
in CR2, there were 86 (49%) events in 174 patients at 18
months (Fig. 5). For T-ALL, venetoclax [40], navitoclax[41] and the anti-CD38 monoclonal daratumumab have
shown promise [42,43].
Newer-generation CAR-Ts with enhanced expansion
and long-term persistence may prevent post-SCT relapse
or even replace the need for SCT. Nevertheless, disease
recurrence in ALL is associated with a long latency, and
careful long-term follow-up will be required. This study
provides the background comparative data required to
evaluate the benefit of the new drugs. A caveat is the
high cost of immunotherapy and its non-availability to
patients in low- and middle-income countries where
most cases of ALL occur. For these newer therapies to
make a significant impact to global outcomes of child-
hood ALL, this is a gap that needs to be bridged.Author contribution statement
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